Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Granisetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 12/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | HTR3B | O95264 | 1/20 | 1.00 |
| ▸ | CHRNB2 | P17787 | 1/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 1/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 1.00 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.91 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.91 |
| ▸ | TSHR | P16473 | 1/20 | 0.91 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.91 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.91 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Granisetron SCHEMBL29372622 | 1.00 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL13660190 | 1.00 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL30372601 | 1.00 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL4109977 | 1.00 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL13287290 | 1.00 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL16642163 | 1.00 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL445223 | 1.00 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL34178 | 1.00 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL4890 | 1.00 | HTR3A (1.00) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 | |
| Granisetron SCHEMBL33433 | 0.99 | HTR3A (0.98) | HTR3AHTR3ESLC22A2HTR3BCHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 25568 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144776-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | ALTO NEUROSCIENCE, INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075410-A | Dry powder composition for intranasal delivery | — | 2026-05-26 | — | — | CN | claimed |
| US-20260130929-A1 | USE OF NK1 ANTAGONIST PRODRUG COMPOUND IN COMBINATION WITH 5-HT3 RECEPTOR ANTAGONIST | SHANGHAI SHENGDI PHARMACEUTICAL CO LTD (CN) | 2026-05-14 | — | — | US | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| WO-2026090164-A1 | COMPOSITIONS COMPRISING ELISMETREP AND A SECOND THERAPEUTIC AGENT FOR TREATING OR PREVENTING MIGRAINE OR PAIN | KALLYOPE, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4727627-A1 | AEROSOL-GENERATING DEVICE WITH IMPROVED AIRFLOW | Alexza Pharmaceuticals, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4725483-A1 | COMBINATION COMPRISING AT LEAST ONE 5-HT2A RECEPTOR ANTAGONIST AND AT LEAST ONE 5-HT3 RECEPTOR ANTAGONIST AND ITS MEDICAL USE | Université de Bordeaux (FR) | 2026-04-15 | — | — | EP | claimed |
| EP-4719552-A1 | INDUCTION OF GENERAL ANESTHESIA IN ADULTS UNDERGOING ELECTIVE SURGERY | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2026-04-08 | — | — | EP | claimed |
| EP-0662822-A1 | TWO-PHASE MATRIX FOR SUSTAINED RELEASE DRUG DELIVERY DEVICE | CYGNUS, INC. (US) | 1995-07-19 | — | — | EP | claimed |
| EP-0650355-A1 | MEDICAMENTS FOR THE TREATMENT OF VISCERAL PAIN AND MIGRAINE | SMITHKLINE BEECHAM PLC (GB) | 1995-05-03 | — | — | EP | claimed |
| WO-1994021257-A1 | USE OF GRANISETRON FOR THE TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING | SMITHKLINE BEECHAM PLC (GB) | 1994-09-29 | — | — | WO | claimed |
| CN-1089469-A | Be used for the lasting two-phase matrix that discharges the transporter of medicine | CYGNUS THERAPEUTIC SYSTEMS (US) | 1994-07-20 | — | — | CN | claimed |
| WO-1994007468-A1 | TWO-PHASE MATRIX FOR SUSTAINED RELEASE DRUG DELIVERY DEVICE | CYGNUS THERAPEUTIC SYSTEMS (US) | 1994-04-14 | — | — | WO | claimed |
| WO-1994001095-A2 | MEDICAMENTS FOR THE TREATMENT OF VISCERAL PAIN AND MIGRAINE | SMITHKLINE BEECHAM PLC (GB) | 1994-01-20 | — | — | WO | claimed |
| EP-0567498-A1 | PHARMACEUTICAL COMPOSITION CONTAINING GRANISETRON AND DEXAMETHASONE | SMITHKLINE BEECHAM PLC (GB) | 1993-11-03 | — | — | EP | claimed |
| EP-0506813-A1 | 5-HT 3? ANTAGONISTS FOR TREATMENT OF NAUSEA, BRADYCARDIA OF HYPOTENSION ASSOCIATED WITH MYOCARDIAL INSTABILITY | Beecham Group p.l.c. (GB) | 1992-10-07 | — | — | EP | claimed |
| WO-1992012716-A1 | PHARMACEUTICAL COMPOSITION CONTAINING GRANISETRON AND DEXAMETHASONE | SMITHKLINE BEECHAM P.L.C. (GB) | 1992-08-06 | — | — | WO | claimed |
| WO-1991009593-A2 | 5-HT3 ANTAGONISTS FOR TREATMENT OF NAUSEA, BRADYCARDIA OF HYPOTENSION ASSOCIATED WITH MYOCARDIAL INSTABILITY | BEECHAM GROUP PLC (GB) | 1991-07-11 | — | — | WO | claimed |